Posted on

“Biopeptides are going to be the key ingredients in the cosmetic medicine treatments of the future”

“Biopeptides are going to be the key ingredients in the cosmetic medicine treatments of the future”

Dr Yong Ji Chung, president of the biotechnology multinational Caregen, gave a paper on ‘Biopeptides in cosmetic medicine and their future in the sector’ at a conference organised by IT Pharma.

The conference on cosmetic medicine, organised by IT Pharma, was held on Saturday 1 September in Hotel Hiberus in Zaragoza.

Last weekend, Dr Chung, president and founder of the Korean multinational Caregen Co., which produces and distributes cosmetic medical products, gave a paper on ‘Biopeptides in cosmetic medicine and their future in the sector’ at Hotel Hiberus in Zaragoza.

In it he pointed out that ‘a great many ingredients have been used for cosmetic medicine in the past, but modern-day biopeptides are much more powerful and effective for a multitude of cases and patients.’ While the Korean company is involved in ongoing research into these amino acid chains, its president stressed that ‘Caregen has managed to develop more than 450 biopeptides, which will generate numerous applications in the future. Many active ingredients have been used in the aesthetic market over time, but peptides are much more powerful in comparison. That is because they act just like our own growth factors and cytokines, and this makes them much more effective. So, in view of the current conditions of the aesthetic market, peptides are going to be the key ingredients in treatments in the future“.

The event organised by IT Pharma in collaboration with TOV Medical also included a round table afterwards with the participation of Dr Chung, Dr Juan Miguel Pérez Díaz from Madrid’s Clínica Pérez Díaz, Dr Rafael Spagnuolo from Clínica Spagnuolo in Marbella and Dr Inma González, the founder of CISIG. The participants shared their experiences with current cosmetic medical cases, the types of treatment most demanded by patients nowadays, the challenges facing the sector and new trends on their way in.

PICTURES ON FACEBOOK

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

Make a comment

Posted on

IT Pharma attends the IMCAS World Congress in Paris

IT Pharma attends the IMCAS World Congress in Paris

IT Pharma attended the IMCAS World Congress in Paris to introduce Prostrolane Inner B of Caregen

The Navarran group made the most of the congress to sign the exclusive distribution agreement in Spain and Mexico for the Prostrolane line by Caregen.

On 1st February, IT Pharma attended the IMCAS WORLD CONGRESS on aesthetic medicine, which took place in Paris, where it collaborated by exhibiting and introducing Prostrolane Inner B., by Caregen Co., assisted by Dr Chung, CEO of the Korean firm.

Doctor Juan Miguel Pérez from the Pérez Díaz Clinic – a regular collaborator of the group – gave a speech about the product and revealed ten clinical cases in which the effectiveness and quality of Inner B. was left undisputable, accompanying other collaborating medical professionals from the Korean group.

Taking full advantage of the visit to the French capital, an importation and exclusive distribution agreement was signed with Caregen for the Prostrolane line. The agreement was signed by Dr Chung and the IT Pharma management, which has reached an agreement with TOV Medical, collaborators in distribution in Spain, who have been given the responsibility for marketing Inner B. within Spain.

The congress concluded with a gala dinner, attended by all the trusted distributers and doctors from the Korean firm.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

Make a comment